$ABBV

AI Analysis

Generated on May 18, 2026

AI Score
74/ 100
Buy$ABBV

AbbVie Inc.

$ABBVNYSEHealthcareLarge-Cap

AbbVie discovers, develops, manufactures, and sells pharmaceuticals worldwide focusing on immunology, oncology, and neuroscience.

Market Cap
$340B
Revenue (TTM)
$58.2B
+5.8%
Net Income (TTM)
$8.5B
+22.5%
EPS (TTM)
$4.82
P/E Ratio
38.5
Dividend Yield
3.2%
52-Week Range
$155-$205
Beta
0.58
Dimension Scores
Fundamental
78
Technical
70
Sentiment
74
Risk / Reward
75
Momentum
68
FundTechSentRiskMome
Financial Health
Profitability
75moderate
Growth
72moderate
Liquidity
70moderate
Solvency
65moderate
Efficiency
76moderate

Valuation, technical analysis, investment thesis, risk assessment and more for $ABBV

Free · No credit card required

Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.

Explore more

Analyze any stock with AI

Get a structured equity research report covering fundamentals, technicals, sentiment, risk, and investment thesis — in about 60 seconds.